TKI dasatinib monotherapy for a patient with Ph-like ALL bearing ATF7IP/PDGFRB translocation

Kenichiro Kobayashi, Naoyuki Miyagawa, Kazumasa Mitsui, Masaki Matsuoka, Yasuko Kojima, Hiroyuki Takahashi, Kaori Ootsubo, Junichi Nagai, Hitomi Ueno, Takeshi Ishibashi, Sara Sultana, Yoko Okada, Shingo Akimoto, Hajime Okita, Kimikazu Matsumoto, Hiroaki Goto, Nobutaka Kiyokawa, Akira Ohara

Research output: Contribution to journalArticlepeer-review

55 Citations (Scopus)


We report a 10-year-old male with relapsing Ph-like acute lymphoblastic leukemia (ALL) bearing ATF7IP/PDGFRB translocation. He was refractory to conventional therapy, and was finally treated with single-agent second-generation TKI dasatinib. The therapeutic response was prompt, with the disappearance of minimum residual disease (MRD) based on genomic PCR analysis within 3 months, and he has maintained complete molecular remission for 12 months. This case report describes an early-phase response to TKI monotherapy on Ph-like ALL, and technical tips for MRD monitoring on long-term follow-up.

Original languageEnglish
Pages (from-to)1058-1060
Number of pages3
JournalPediatric Blood and Cancer
Issue number6
Publication statusPublished - 2015 Jun 1
Externally publishedYes


  • Genomic PCR
  • MRD
  • PDGFRB fusion
  • Ph-like ALL
  • TKI

ASJC Scopus subject areas

  • Pediatrics, Perinatology, and Child Health
  • Hematology
  • Oncology


Dive into the research topics of 'TKI dasatinib monotherapy for a patient with Ph-like ALL bearing ATF7IP/PDGFRB translocation'. Together they form a unique fingerprint.

Cite this